This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Jim Cramer's 'Mad Money' Recap: Fewer Jobs = Bull Market

When asked about sales overseas, Chirico said Italy and southern Europe are still weak but there is growing strength in northern Europe. He said Asia remains another area of opportunity for PVH over the long term.

When asked about the difficulty in meeting those year-end targets, Chirico said he doesn't expect "heroic efforts" in order to meet and beat its targets.

Cramer said he remains a believer in PVH and the strength of its brands.

Off the Charts

In the "Off The Charts" segment, Cramer went head to head with colleague Ed Ponsi over the direction of the big-cap biotech stocks, using the iShares Nasdaq Biotech ETF (IBB).

Ponsi noted that between November and March of this year the biotechs were roaring. But then in late February, after a wave of new IPOs and secondary offerings, the group crashed hard, down 19% in a matter of weeks. The biotechs saw their lows in April and have since been in consolidation mode.

That was until last week, when the group quietly broke above its 50-day moving average and out of a symmetrical triangle pattern.

Ponsi noted that Celgene (CELG), after a 38% retracement, is now signaling a bullish crossover in its MACD momentum indicator.

Other notable biotechs, like Regeneron (REGN), down 20%, is also now signaling strength, as is Isis Pharmaceuticals (ISIS), whose most recent pullback was on very light volume, signaling the buyers are still in control.

Cramer said he's in agreement with Ponsi and feels these great left-for-dead names are once again in bull market mode.

Executive Decision: Robert Greenberg

In his second "Executive Decision" segment, Cramer sat down on location with Robert Greenberg, chairman and CEO of Skechers (SKX) and CFO and COO David Weinberg. Shares of Skechers are up 38% so far this year.

Greenberg said footwear remains a hot commodity and Skechers is one of the few companies that can say it's racing to keep up with inventory and can raise prices if it wants to.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs